#Cyprus #Limassol #T-Cell Engagers #InSysBio #BeOne Medicines

InSysBio Expands Partnership with BeOne Medicines

In a significant move enhancing its role in the pharmaceutical industry, InSysBio, a leader in Quantitative Systems Pharmacology (QSP) modeling, has announced the extension of its collaboration with BeOne Medicines, a global oncology company. This partnership is aimed at advancing the understanding and clinical application of T-cell engagers, a promising class of immunotherapies.

The strategic focus of this project is to implement mechanistic translational modeling that supports the identification of a minimal recommended starting dose for clinical trials, as well as a step-up dosing regimen tailored to mitigate cytokine release syndrome. This approach is designed to optimize the design of dose-escalation clinical studies, which are crucial for the successful development of new cancer therapies.

Oleg Demin Jr, the Head of Oncology and Immuno-Oncology at InSysBio, emphasized the importance of trimer-based mechanistic modeling in guiding the selection of appropriate starting doses for first-in-human trials. He stated, "This modeling is vital for ensuring that the dose used is effective while avoiding under-dosing that could compromise results or require multiple escalations during the trial."

By leveraging InSysBio's comprehensive QSP model for T-cell engagers, the collaboration aims to effectively bridge the gap between laboratory and clinical outcomes. This model is particularly adept at capturing the differences between in vitro (test tube) experiments and real-world clinical settings, thereby enhancing the preclinical-to-clinical translation process. It not only predicts starting doses but also facilitates the determination of step-up dosing regimens based on robust preclinical data.

About InSysBio

Founded in 2004, InSysBio comprises a group of QSP-focused companies based in Limassol, Cyprus, and Edinburgh, UK. The organization has cultivated a strong portfolio through numerous collaborations, successfully completing over 100 projects with leading pharmaceutical firms and innovative biotech companies. Utilizing cutting-edge QSP methodologies, InSysBio has been instrumental in helping partners make informed decisions at critical stages of drug research and development.

For those interested in learning more about InSysBio's services or to explore their innovative solutions, further details can be found on their website at www.insysbio.com.

As advancements in oncology continue to evolve, collaborations like that of InSysBio and BeOne Medicines represent a critical step forward. By utilizing state-of-the-art modeling techniques, these organizations aim to enhance the efficacy of treatments available to patients battling cancer, emphasizing innovation and precision in medical research.